RGIN — Regenicin Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$11.22m
Annual income statement for Regenicin, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2018 September 30th | 2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Standards: | USG | USG | USG | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.54 | 0.737 | 0.511 | 0.636 | 0.601 |
| Operating Profit | -0.54 | -0.737 | -0.511 | -0.636 | -0.601 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.559 | -0.758 | -0.56 | -0.671 | -0.639 |
| Net Income After Taxes | -0.559 | -0.758 | -0.56 | -0.671 | -0.639 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.559 | -0.758 | -0.56 | -0.671 | -0.639 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.63 | -0.829 | -0.631 | -0.741 | -0.692 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.004 | -0.005 | -0.004 | -0.005 | -0.005 |